NovoCure
NVCR
236 hedge funds and large institutions have $1.59B invested in NovoCure in 2024 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 75 increasing their positions, 71 reducing their positions, and 45 closing their positions.
303% more call options, than puts
Call options by funds: $22.4M | Put options by funds: $5.55M
14% more capital invested
Capital invested by funds: $1.4B → $1.59B (+$191M)
2.99% more ownership
Funds ownership: 83.35% → 86.34% (+3%)
6% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 71
4% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 45
0% less funds holding
Funds holding: 237 → 236 (-1)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$53.6M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$49.8M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$30.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.4M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$12.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$16.7M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$12.4M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$10.3M |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$9.84M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$8.23M |
NVCR Hedge Fund Activity: Q2 2024 in Review
236 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q2 2024, worth a combined $1.59B — up 14% from $1.4B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new NVCR positions and 45 closed out — a net gain of 2 holders — while 75 added to existing stakes and 71 trimmed.
The largest buyer was BlackRock, adding an estimated $53.6M. The largest seller was Morgan Stanley, cutting an estimated $16.7M.
- 236 institutional investors held NovoCure (NVCR) as of Q2 2024, down from 237 in Q1 2024.
- Funds reported $1.59B of NovoCure stock for Q2 2024, up 14% quarter-over-quarter.
- 47 funds opened new NovoCure positions in Q2 2024 and 45 closed out, a net change of +2 holders.
- The largest NovoCure buyer in Q2 2024 was BlackRock, an estimated $53.6M added.
- The largest NovoCure seller in Q2 2024 was Morgan Stanley, an estimated $16.7M sold.
Based on aggregated 13F filings for Q2 2024.